WARRANT TO PURCHASE COMMON STOCK OF PHARMACOPEIA DRUG DISCOVERY, INC.Warrant Agreement • May 12th, 2006 • Pharmacopeia Drug Discovery Inc • Services-commercial physical & biological research • Delaware
THIS CERTIFIES THAT, for value received, «NAME» or its permitted transferees or permitted assigns (the “Holder”), from and after the Issuance Date (as defined below), and subject to the terms and conditions herein set forth, is entitled to purchase from Pharmacopeia Drug Discovery, Inc., a Delaware corporation (the “Company”), at any time before 5:00 p.m. New York City time on the earlier to occur of (i) March 24, 2011 and (ii) the effective date of a termination under the Product Development Agreement (as defined below) by the Company, in the case of Sections 12.2.1 or 12.2.4(c) of the Product Development Agreement, or by GSK (as defined in the Product Development Agreement), in the case of Section 12.2.5 of the Product Development Agreement (the “Termination Date”), «WordNumberOfWarrantShares» («NumberOfWarrantShares») shares (as adjusted from time to time pursuant to Section 2 hereof, the “Warrant Shares”) of the Company’s common stock, $0.01 par value per share (the “Common Stock”)
PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT AMONG SMITHKLINE BEECHAM CORPORATION DOING BUSINESS AS GLAXOSMITHKLINE, GLAXO GROUP LIMITED AND PHARMACOPEIA DRUG DISCOVERY, INC. DATED AS OFProduct Development and Commercialization Agreement • May 12th, 2006 • Pharmacopeia Drug Discovery Inc • Services-commercial physical & biological research • Delaware
THIS PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT is made as of the 24th day of March, 2006 (the “EFFECTIVE DATE”) by and between SmithKline Beecham Corporation, doing business as GlaxoSmithKline, a Pennsylvania corporation having a principal place of business at One Franklin Plaza, 200 N 16th Street, Philadelphia, PA 19102 (“SB Corp”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GGL”), SB Corp and GGL being collectively referred to hereinafter as “GSK”; and Pharmacopeia Drug Discovery, Inc., a Delaware corporation having a principal place of business at 3000 Eastpark Boulevard, Cranbury, New Jersey 08512 (“Pharmacopeia”). Pharmacopeia and GSK are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
LICENSE AGREEMENT between PHARMACOPEIA DRUG DISCOVERY INC. and BRISTOL-MYERS SQUIBB COMPANYLicense Agreement • May 12th, 2006 • Pharmacopeia Drug Discovery Inc • Services-commercial physical & biological research • Delaware
THIS LICENSE AGREEMENT (this “Agreement”) is made and entered into as of March 27, 2006 (the “Effective Date”), by and between Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”), and Pharmacopeia Drug Discovery Inc., a Delaware corporation, having its principal office at 3000 Eastpark Boulevard, Cranbury, New Jersey 08512 (“Pharmacopeia”). BMS and Pharmacopeia are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
